ATRX and central nervous system cancer: After the IDH mutation status was confirmed to be related to the prognosis of patients with GBMs, a subsequent study reported that the chromosome 1p/19q codeletion status, O6-methylguanine-DNA methyltransferase (MGMT) promoter region genotype, a-thalassemiamental retardation syndrome X (ATRX), and amplification of the epidermal growth factor receptor (EGFR) played more important roles in the prognosis and treatment prediction of gliomas (39, 40).